blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2032127

EP2032127 - TREATING PSYCHOLOGICAL CONDITIONS USING MUSCARINIC RECEPTOR M1 ANTAGONISTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  29.05.2015
Database last updated on 14.09.2024
Most recent event   Tooltip13.10.2017Lapse of the patent in a contracting state
New state(s): HU, TR		published on 15.11.2017  [2017/46]
Applicant(s)For all designated states
Theracos, Inc.
225 Cedar Hill Street, Suite 200
Marlborough, MA 01752 / US
[2013/50]
Former [2009/11]For all designated states
Theracos, Inc.
550 Del Rey Avenue
Sunnyvale, CA 94085-3528 / US
Inventor(s)01 / SEED, Brian
2 Hawthorne Place
Boston, MA 02114 / US
02 / MECHANIC, Jordan
7137 Coronado Drive
San Jose, CA 95129 / US
 [2014/23]
Former [2009/11]01 / SEED, Brian
21 Fairway Drive, 2121
Derry, New Hampshire 03038 / US
02 / MECHANIC, Jordan
30 Newell Road, 17
Palo Alto, California 94303 / US
Representative(s)Cole, William Gwyn
Avidity IP
Broers Building
Hauser Forum
21 J J Thomson Avenue
Cambridge CB3 0FA / GB
[N/P]
Former [2014/30]Cole, William Gwyn
avidity IP
Kestrel House
Falconry Court
Baker's Lane
Epping, Essex CM16 5DQ / GB
Former [2009/45]Cole, William Gwyn
HLBBshaw Merlin House Falconry Court Baker's Lane
Epping, Essex CM16 5DQ / GB
Former [2009/11]Cole, William Gwyn
HLBBshaw Merlin House Falconry Court Baker's Lane
GB-Epping, Essex CM16 5DQ / GB
Application number, filing date07784456.115.06.2007
[2009/11]
WO2007US71356
Priority number, dateUS20060805066P16.06.2006         Original published format: US 805066 P
US20060829225P12.10.2006         Original published format: US 829225 P
US2007076314514.06.2007         Original published format: US 763145
[2009/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2007147123
Date:21.12.2007
Language:EN
[2007/51]
Type: A1 Application with search report 
No.:EP2032127
Date:11.03.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 21.12.2007 takes the place of the publication of the European patent application.
[2009/11]
Type: B1 Patent specification 
No.:EP2032127
Date:23.07.2014
Language:EN
[2014/30]
Search report(s)International search report - published on:US21.12.2007
(Supplementary) European search report - dispatched on:EP28.10.2009
ClassificationIPC:A61K31/135, A61K31/137, A61K31/138, A61K31/15, A61K31/165, A61K31/343, A61K31/381, A61K31/4525, A61K31/55, A61K31/551, A61K31/5513, A61P25/18, A61K45/06
[2014/05]
CPC:
A61K45/06 (EP,KR,US); A61K31/135 (EP,US); A61K31/137 (EP,KR,US);
A61K31/138 (EP,US); A61K31/15 (EP,US); A61K31/165 (EP,US);
A61K31/343 (EP,KR,US); A61K31/381 (EP,US); A61K31/4525 (EP,US);
A61K31/55 (EP,US); A61K31/551 (EP,US); A61K31/5513 (EP,US);
A61P1/04 (EP); A61P1/14 (EP); A61P15/00 (EP);
A61P15/10 (EP); A61P25/00 (EP); A61P25/02 (EP);
A61P25/14 (EP); A61P25/16 (EP); A61P25/18 (EP);
A61P25/20 (EP); A61P25/22 (EP); A61P25/24 (EP);
A61P25/28 (EP); A61P25/30 (EP); A61P25/32 (EP);
A61P25/34 (EP); A61P25/36 (EP); A61P29/00 (EP);
A61P3/02 (EP); A61P3/04 (EP); A61P3/06 (EP);
A61P43/00 (EP); A61P5/00 (EP); A61P5/24 (EP) (-)
C-Set:
A61K31/135, A61K2300/00 (US,EP);
A61K31/137, A61K2300/00 (US,EP);
A61K31/138, A61K2300/00 (US,EP);
A61K31/15, A61K2300/00 (US,EP);
A61K31/165, A61K2300/00 (EP,US);
A61K31/343, A61K2300/00 (US,EP);
A61K31/381, A61K2300/00 (EP,US);
A61K31/4525, A61K2300/00 (EP,US);
A61K31/5513, A61K2300/00 (EP,US);
A61K31/551, A61K2300/00 (US,EP);
A61K31/55, A61K2300/00 (EP,US)
(-)
Former IPC [2009/11]A61K31/00, A61K45/06
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/11]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:BEHANDLUNG PSYCHOLOGISCHER ERKRANKUNGEN MITTELS MUSCARINREZEPTOR-M1-ANTAGONISTEN[2009/11]
English:TREATING PSYCHOLOGICAL CONDITIONS USING MUSCARINIC RECEPTOR M1 ANTAGONISTS[2009/11]
French:TRAITEMENT DE PATHOLOGIES PSYCHOLOGIQUES AU MOYEN D'ANTAGONISTES DU RÉCEPTEUR MUSCARINIQUE M1[2009/11]
Entry into regional phase15.01.2009National basic fee paid 
15.01.2009Search fee paid 
15.01.2009Designation fee(s) paid 
15.01.2009Examination fee paid 
Examination procedure15.01.2009Examination requested  [2009/11]
19.01.2010Amendment by applicant (claims and/or description)
17.11.2010Despatch of a communication from the examining division (Time limit: M04)
28.03.2011Reply to a communication from the examining division
20.04.2012Despatch of a communication from the examining division (Time limit: M04)
30.08.2012Reply to a communication from the examining division
24.01.2014Communication of intention to grant the patent
30.05.2014Fee for grant paid
30.05.2014Fee for publishing/printing paid
30.05.2014Receipt of the translation of the claim(s)
Divisional application(s)EP12194224.7  / EP2666358
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.11.2010
Opposition(s)24.04.2015No opposition filed within time limit [2015/27]
Fees paidRenewal fee
05.06.2009Renewal fee patent year 03
24.05.2010Renewal fee patent year 04
13.06.2011Renewal fee patent year 05
14.06.2012Renewal fee patent year 06
10.06.2013Renewal fee patent year 07
12.06.2014Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.06.2007
AT23.07.2014
BE23.07.2014
CY23.07.2014
CZ23.07.2014
DK23.07.2014
EE23.07.2014
ES23.07.2014
FI23.07.2014
IT23.07.2014
LT23.07.2014
LV23.07.2014
MC23.07.2014
MT23.07.2014
NL23.07.2014
PL23.07.2014
RO23.07.2014
SE23.07.2014
SI23.07.2014
SK23.07.2014
TR23.07.2014
BG23.10.2014
GR24.10.2014
IS23.11.2014
PT24.11.2014
[2017/39]
Former [2017/03]AT23.07.2014
BE23.07.2014
CY23.07.2014
CZ23.07.2014
DK23.07.2014
EE23.07.2014
ES23.07.2014
FI23.07.2014
IT23.07.2014
LT23.07.2014
LV23.07.2014
MC23.07.2014
MT23.07.2014
NL23.07.2014
PL23.07.2014
RO23.07.2014
SE23.07.2014
SI23.07.2014
SK23.07.2014
BG23.10.2014
GR24.10.2014
IS23.11.2014
PT24.11.2014
Former [2016/32]AT23.07.2014
BE23.07.2014
CY23.07.2014
CZ23.07.2014
DK23.07.2014
EE23.07.2014
ES23.07.2014
FI23.07.2014
IT23.07.2014
LT23.07.2014
LV23.07.2014
MC23.07.2014
NL23.07.2014
PL23.07.2014
RO23.07.2014
SE23.07.2014
SI23.07.2014
SK23.07.2014
BG23.10.2014
GR24.10.2014
IS23.11.2014
PT24.11.2014
Former [2016/09]AT23.07.2014
CY23.07.2014
CZ23.07.2014
DK23.07.2014
EE23.07.2014
ES23.07.2014
FI23.07.2014
IT23.07.2014
LT23.07.2014
LV23.07.2014
MC23.07.2014
NL23.07.2014
PL23.07.2014
RO23.07.2014
SE23.07.2014
SI23.07.2014
SK23.07.2014
BG23.10.2014
GR24.10.2014
IS23.11.2014
PT24.11.2014
Former [2015/50]AT23.07.2014
CY23.07.2014
CZ23.07.2014
DK23.07.2014
EE23.07.2014
ES23.07.2014
FI23.07.2014
IT23.07.2014
LT23.07.2014
LV23.07.2014
NL23.07.2014
PL23.07.2014
RO23.07.2014
SE23.07.2014
SI23.07.2014
SK23.07.2014
BG23.10.2014
GR24.10.2014
IS23.11.2014
PT24.11.2014
Former [2015/23]AT23.07.2014
CY23.07.2014
CZ23.07.2014
DK23.07.2014
EE23.07.2014
ES23.07.2014
FI23.07.2014
IT23.07.2014
LT23.07.2014
LV23.07.2014
NL23.07.2014
PL23.07.2014
RO23.07.2014
SE23.07.2014
SK23.07.2014
BG23.10.2014
GR24.10.2014
IS23.11.2014
PT24.11.2014
Former [2015/22]AT23.07.2014
CY23.07.2014
DK23.07.2014
ES23.07.2014
FI23.07.2014
IT23.07.2014
LT23.07.2014
LV23.07.2014
NL23.07.2014
PL23.07.2014
RO23.07.2014
SE23.07.2014
BG23.10.2014
GR24.10.2014
IS23.11.2014
PT24.11.2014
Former [2015/12]AT23.07.2014
CY23.07.2014
ES23.07.2014
FI23.07.2014
LT23.07.2014
LV23.07.2014
NL23.07.2014
PL23.07.2014
SE23.07.2014
BG23.10.2014
GR24.10.2014
IS23.11.2014
PT24.11.2014
Former [2015/11]CY23.07.2014
ES23.07.2014
FI23.07.2014
LT23.07.2014
PL23.07.2014
SE23.07.2014
BG23.10.2014
GR24.10.2014
PT24.11.2014
Former [2015/10]ES23.07.2014
FI23.07.2014
LT23.07.2014
SE23.07.2014
BG23.10.2014
Former [2015/09]FI23.07.2014
LT23.07.2014
SE23.07.2014
Former [2015/08]LT23.07.2014
Documents cited:Search[XY]US3953430  (SAFIR SIDNEY ROBERT) [X] 1,5,12,13 * column 1, lines 5-15 * * column 4, lines 57,58 * * column 6, lines 24,25 * [Y] 1-15;
 [PX]WO2006113485  (UNIV MICHIGAN STATE [US], et al) [PX] 1,5,12,13 * claims 112,132,133,144 *;
 [PX]WO2006127418  (US GOV HEALTH & HUMAN SERV [US], et al) [PX] 1-15 * page 2, lines 4-9 * * page 10, line 9 - page 14, line 15 ** page 22, lines 1-9 *;
 [Y]  - CHAU D T ET AL, "Nucleus accumbens muscarinic receptors in the control of behavioral depression: Antidepressant-like effects of local M1 antagonist in the porsolt swim test", NEUROSCIENCE, (20010614), vol. 104, no. 3, ISSN 0306-4522, pages 791 - 798, XP002550693 [Y] 1-15 * page 794; table 1 * * page 796, column R *

DOI:   http://dx.doi.org/10.1016/S0306-4522(01)00133-6
International search[X]US2004082653  (NONAKA SHIGEYUKI [JP], et al);
 [Y]US2005227998  (VOELKER KIRK [US])
by applicantUS3660380
 US3743734
 US3953430
 US4168269
 US4172831
 US4381301
 US5140025
 US5296483
 US5312817
 US5324832
 US5445829
 US5472704
 US5672356
 US6080736
 US6150354
 US6310177
 US6312717
 US6319919
 US6379696
 US6403597
 US6465006
 US6482440
 US6512010
 US6517864
 US6524621
 US6528080
 US6537579
 US6541020
 US6544548
 US6548084
 US6562375
 US6565883
 US6569463
 US6589563
 US6589549
 US6596308
 US6599529
 US6607751
 US6613361
 US6613358
 US6624200
 US6635680
 US6638521
 US2004082653
 US2005227998
    - CHAU, D.T. ET AL., NEUROSCIENCE, (2001), vol. 104, no. 3, pages 791 - 8
    - MIYAKAWA, T. ET AL., J. NEUROSCI., (2001), vol. 21, no. 14, pages 5239 - 50
    - ROGOZ, Z.; SKUZA, G.; SOWINSKA, H., POL. J. PHARMACOL. PHARM., (1981), vol. 31, pages 615 - 26
    - HAMMER, R.; KOSS, F.W., SCAND. J. GASTROENTEROL., (1979), vol. 14, no. 57, pages 1 - 6
    - BYMASTER, F.P. ET AL., J. PHARMACOL. EXP. THER., (1993), vol. 267, no. 1, pages 16 - 24
    - MUNSON, P.J.; RODBARD, D., ANAL. BIOCHEM., (1980), vol. 107, pages 220 - 39
    - BUCKLEY ET AL., MOLECULAR PHARMACOLOGY, (1989), vol. 35, pages 469 - 76
    - BOLDEN ET AL., J PHARMACOL EXP THER, (1992), vol. 260, pages 576 - 80
    - HAMMER, R.; KOSS, F.W.; SCAND. J., GASTROENTEROL., (1979), vol. 14, no. 57, pages 1 - 6
    - BYMASTER ET AL., CURR DRUG TARGETS CNS NEUROL DISORD, (2002), vol. 1, pages 163 - 181
    - SMOLDERS ET AL., J NEUROCHEM, (1997), vol. 68, pages 1942 - 1948
    - IZURIETA-SANCHEZ ET AL., EUR J PHARMACOL, (2000), vol. 399, pages 151 - 160
    - BERRIDGE; ROBINSON, BRAIN RES BRAIN RES REV, (1998), vol. 28, pages 309 - 369
    - CRESPO ET AL., JNEUROSCI, (2006), vol. 26, pages 6004 - 6010
    - DI CHIARA; IMPERATO, PROC NATL ACAD SCI USA, (1988), vol. 85, pages 5274 - 5278
    - HERNANDEZ; HOEBEL, LIFE SCI, (1988), vol. 42, pages 1705 - 1712
    - ZAHM; BROG, NEUROSCIENCE, (1992), vol. 50, pages 751 - 767
    - HOEBEL ET AL., PSYCHOPHARMACOLOGY (BERL, (1983), vol. 81, pages 15 8 - 163
    - RADA ET AL., PHARMACOL BIOCHEM BEHAV, (1996), vol. 53, pages 809 - 816
    - ACQUAS; DI CHIARA, JNEUROCHEM, (1992), vol. 58, pages 1620 - 1625
    - DIANA ET AL., JPHARMACOL EXP THER, (1995), vol. 272, pages 781 - 785
    - POTHOS ET AL., BRAIN RES, (1991), vol. 566, pages 348 - 350
    - RADA ET AL., PSYCHOPHARMACOLOGY (BERL, (2001), vol. 157, pages 105 - 110
    - SCHMIDT ET AL., EUR J NEUROSCI, (2006), vol. 23, pages 219 - 228
    - FISEROVA ET AL., PSYCHOPHARMACOLOGY (BERL, (1999), vol. 142, pages 85 - 94
    - RADA ET AL., NEUROPHARMACOLOGY, (1991), vol. 30, pages 1133 - 1136
    - MARK ET AL., BRAIN RES, (1995), vol. 688, pages 184 - 188
    - RADA; HOEBEL, BRAIN RES, (2001), vol. 888, pages 60 - 65
    - RADA; HOEBEL, EUR JPHARMACOL, (2005), vol. 508, pages 131 - 138
    - RADA ET AL., PHARMACOL BIOCHEM BEHAV, (2004), vol. 79, pages 599 - 605
    - COLANTUONI ET AL., OBES RES, (2002), vol. 10, pages 478 - 488
    - EVELEIGH ET AL., MOL PHARMACOL, (1989), vol. 35, pages 477 - 483
    - SCHUDT ET AL., EUR J PHARMACOL, (1989), vol. 165, pages 87 - 96
    - ELTZE, EUR J PHARMACOL, (1990), vol. 180, pages 161 - 168
    - FEIFEL ET AL., EUR J PHARMACOL, (1991), vol. 195, pages 115 - 123
    - KILIAN ET AL., AGENTS ACTIONS SUPPL, vol. 34, pages 131 - 147
    - NILSSON BM, J. MED. CHEM., (2006), vol. 49, pages 4023 - 4034
    - HUANG ET AL., DRUG DEV. IND. PHARM., (2003), vol. 29, page 79
    - PEARNCHOB ET AL., DRUG DEV. IND. PHARM., (2003), vol. 29, page 925
    - MAGGI ET AL., EUR. J. PHARM. BIOPHARM., (2003), vol. 55, page 99
    - KHANVILKAR ET AL., DRUG DEV. IND. PHARM., (2002), vol. 228, page 601
    - SCHMIDT ET AL., INT. J. PHARM., (2001), vol. 216, page 9
    - STERU L ET AL., PYC/OP/ARMACOL, (1985), vol. 85, pages 367 - 70
    - STERU L ET AL., PROG NEURO-PSYCHOPHARMACOL & BIOL PSYCHIAT, (1987), vol. 11, pages 659 - 71
    - CROWLEY JJ ET AL., PHARMACOL BIOCHEM BEH, (2004), vol. 78, no. 2, pages 269 - 74
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.